Abstract
4245 Background: Esophageal cancer, while less frequent among cancers in the U.S., it is highly lethal. In the last decade, adenocarcinoma of the esophagus has had the most rapid increase in rate among solid tumors. Patients presenting with local regional disease often succumb to systemic spread. Preoperative chemoradiotherapy followed by surgery appears to offer a survival advantage over surgery alone; however, efficacy with 5-FU/Platinum based therapy is limited partly by failure to eradicate occult disease. Docetaxel and irinotecan are newer agents that have demonstrated activity in GI malignancies. The objective of this study is to determine the response rate and safety of preoperative docetaxel and irinotecan in patients with carcinoma of the esophagus. Methods: 14 patients, 10 adeno. 4 scc, 13M/1F, 4AA, 10C with resectable esophageal cancer have been enrolled to date. Docetaxel 35 mg/m2and irinotecan 50 mg/m2 were given weekly for 3 consecutive weeks. Following a one week break, docetaxel 30mg/m2 wa...
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
